Sanofi (NASDAQ:SNY) Cut to “Hold” at Wall Street Zen

Wall Street Zen lowered shares of Sanofi (NASDAQ:SNY) from a buy rating to a hold rating in a research report sent to investors on Sunday morning.

Several other equities analysts have also commented on SNY. BNP Paribas Exane lowered Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research report on Monday, April 20th. Weiss Ratings lowered shares of Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, August 3rd. Morgan Stanley set a $49.00 price target on shares of Sanofi in a research report on Wednesday, July 8th. Argus raised shares of Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Finally, Citigroup restated a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $49.50.

Sanofi Price Performance

SNY stock opened at $43.56 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 0.99 and a quick ratio of 0.64. Sanofi has a 1 year low of $40.89 and a 1 year high of $52.68. The firm has a 50-day moving average of $43.34 and a 200 day moving average of $45.01. The company has a market cap of $105.61 billion, a P/E ratio of 22.81, a PEG ratio of 1.08 and a beta of 0.35.

Institutional Investors Weigh In On Sanofi

A number of institutional investors have recently modified their holdings of the stock. Advisory Services Network LLC increased its position in Sanofi by 1.4% during the third quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock worth $743,000 after purchasing an additional 210 shares during the last quarter. Savant Capital LLC boosted its holdings in Sanofi by 2.7% in the 4th quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock valued at $418,000 after purchasing an additional 225 shares during the last quarter. Wesbanco Bank Inc. boosted its holdings in Sanofi by 4.9% in the 4th quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock valued at $239,000 after purchasing an additional 230 shares during the last quarter. IFG Advisory LLC grew its stake in shares of Sanofi by 2.7% in the 4th quarter. IFG Advisory LLC now owns 9,213 shares of the company’s stock valued at $446,000 after buying an additional 244 shares during the period. Finally, Cohen Investment Advisors LLC grew its stake in shares of Sanofi by 2.9% in the 1st quarter. Cohen Investment Advisors LLC now owns 9,480 shares of the company’s stock valued at $457,000 after buying an additional 263 shares during the period. 14.03% of the stock is owned by hedge funds and other institutional investors.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.